Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

Icotrokinra (Icotyde), the first oral IL-23 receptor antagonist for plaque psoriasis, was FDA approved in March 2026 and showed strong efficacy (65% IGA 0/1, 50% PASI 90 at Week 16) versus placebo.

Combination therapy pairing ixekizumab with tirzepatide significantly outperformed ixekizumab alone in psoriatic arthritis patients with obesity or overweight, per the TOGETHER-PsA trial.

Saakshi Khattri, MD, says these advances are shifting psoriasis care toward biologic-level oral options and making conversations about weight and comorbidity easier with patients.

 has historically lagged injectable biologics in efficacy. The 

 approved icotrokinra (Icotyde), the first oral IL-23 receptor antagonist for moderate to severe plaque psoriasis, in March 2026. The ICONIC-LEAD trial found 65% of patients reached an Investigator's Global Assessment score of 0/1 and 50% achieved PASI 90 at week 16, versus 8% and 4% with placebo (

"It's exciting times to be a psoriasis patient, to be a prescriber in the psoriasis space," said Saakshi Khattri, MD, associate professor and director of the Center for Connective Tissue Diseases at the Icahn School of Medicine at Mount Sinai.

Zasocitinib, an investigational TYK2 inhibitor, produced comparable clearance in its phase 3 LATITUDE trials.² Combination therapy targeting metabolic comorbidity also advanced in 2026. The phase 3b TOGETHER-PsA trial found ixekizumab plus tirzepatide produced greater joint disease control than ixekizumab monotherapy in patients with psoriatic arthritis (PsA) and obesity or overweight. Of combination-therapy patients, 31.7% reached ACR50 response plus at least 10% weight loss at week 36, compared with 0.8% on monotherapy (

Clinicians have long observed higher body mass index blunts response to systemic psoriasis therapy, and 2026 trial data now support treating weight alongside skin and joint disease directly. Within the following Q&A interview, Saakshi Khattri, MD, discusses the evolving oral and combination treatment landscape for psoriasis and psoriatic arthritis:

: How are new oral treatment options changing the conversation around psoriasis therapy?

 I'm super stoked to have oral options that have biologic-like efficacy, if I can use that terminology, because historically we've had injectables and we've not had really good oral options that get you clear skin. That's the biggest shift we're seeing in the treatment of psoriasis right now: we have oral options, one that's been approved a few months ago, and others in the pipeline with different MOAs, like the TYK2 inhibitors, that have efficacy comparable to what we'd expect with systemic biologics. It's exciting times to be a psoriasis patient and a prescriber in the psoriasis space, so there's a lot to look forward to.

: New data presented at AAD showed adding weight-loss drugs to standard therapy improved outcomes in psoriatic disease. How has this changed your approach?

Yes, a few months ago we had presentations at the AAD, and not just the AAD but also in the rheum space, in PsA, on combination therapy with weight loss medications and biologics. It showed patients on combination therapy with weight loss medications and biologics for either psoriasis or psoriatic arthritis tend to perform better than patients who were just on biologics for psoriasis or PsA alone. It's exciting, because we know psoriasis and psoriatic arthritis patients have metabolic syndrome, and they tend to have a high BMI. There's data to support patients with a higher BMI don't necessarily respond as robustly to the systemic options we have, or they're more recalcitrant to options that would otherwise work for somebody with a lower BMI.

So to have this in a clinical trial format that shows efficacy of combination therapy is exciting, because we now have data to go by. I think we suspected it would be the case, but until you have a clinical trial that shows efficacy, it's hard to say yes or no. Now, because of that, more and more of my patients are asking me for combination therapy, and I'm advocating for it in my practice for patients who are eligible for weight loss medications based on their BMI and other comorbid conditions.

: Are you optimistic about combination therapy, cautiously optimistic, or waiting for more data?

We've had weight loss drugs for a while now, so we have other indications for which they've been used, and there's a lot of chatter around systemic inflammation with weight loss medications as well. I'm pretty excited to have this now in a clinical trial format with data to support combination therapy use. I'm definitely a proponent in my practice of advocating for it, should a patient meet the criteria for an add-on of a weight loss medication.

I think this has also made the discussion around weight loss or high BMI less of an issue, because historically, talking about a patient's weight has been a sore point, or something that can rub people the wrong way, and clinicians are often hesitant to talk about high BMI in our patients. But with this, people are more open to having the conversation, and I think that's the best outcome that has come from this.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Khattri’s relevant financial disclosures include LEO Pharma, Galderma, Eli Lilly, and Johnson & Johnson.

Johnson & Johnson. FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide. Published March 18, 2026. Accessed August 25, 2026. 

https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide

Takeda. Takeda's zasocitinib delivered rapid and durable skin clearance in phase 3 trials. Published March 28, 2026. Accessed August 25, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase3-clinical-trial-results/

Merola JF, Mease P, Kivitz A, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity. Arthritis Rheumatol. 2026. doi:10.1002/art.70134.

Articles

Saakshi Khattri, MD, discusses oral TYK2 inhibitor and IL-23 antagonist data alongside weight-loss combination therapy reshaping psoriasis and PsA care.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments

Jonathan Downar, MD, PhD, FRCPC, associate professor of the Department of Psychiatry at the University of Toronto and co-founder of Ampa.

Two decades of incremental advances have compressed transcranial magnetic stimulation (TMS) sessions from nearly 40 minutes down to as little as 3, expanding the treatment’s reach to far more patients with 

and other psychiatric conditions, according to Jonathan Downar, MD, PhD, associate professor of psychiatry at the University of Toronto and co-founder of Ampa One, an FDA-cleared TMS device.

Downar has practiced TMS since 2010, the same year he opened a charity TMS clinic in Toronto, now treating roughly 1000 patients annually across 10 machines. He described the field's progress as steady rather than sudden, with a meaningful development arriving every 2 to 3 years since he entered the field.

"In 2010, when I started, TMS sessions were typically 38 minutes long, and over time we were able to discover ways to get them down to about 3 minutes per session, which allowed a lot more patients to come in and made it a lot more scalable," Downar said.

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD

Shrinking Session Time Expands Patient Access

Downar pointed to 2010 as the year the first accelerated TMS study appeared in the literature, describing a protocol delivering 15 sessions over 2 days.

He called reducing the number of clinic visits required to complete a course of treatment one of the field's biggest ongoing priorities.

A second theme Downar highlighted involves pharmacologically enhancing plasticity. He said certain medications acting on specific brain receptors may boost the effect of TMS, potentially extending how long a course of treatment remains effective or lowering the number of sessions needed to achieve it.

Downar also credited advances in neuroimaging, an area tied to his own early research background, with reshaping which brain circuits clinicians target. Over the past 5 to 10 years, imaging studies have generated increasingly detailed maps of the circuitry implicated in depression and other psychiatric conditions.

The THREE-D Trial Set the Template for Shorter Protocols

Downar served as senior author on THREE-D, the 2018 trial published in The Lancet establishing a 3-minute theta-burst protocol as noninferior to older, longer stimulation regimens.

 He said the trial's legacy is visible today in the global adoption of theta-burst-based protocols, with clinicians in many regions now running sessions lasting 3 to 10 minutes instead of 37 minutes or more.

The time saved by shorter sessions has opened a new clinical question, Downar said: what to do with the extra time in a patient visit. Clinicians have begun using it to stimulate more of the brain during a single visit. A recent analysis has shown that 5x5 accelerated repetitive TMS, consisting of 5 sessions per day over 5 consecutive days, compresses overall treatment time from 6 to 1 week.

"Being able to complete an effective session or treatment in 3 minutes allows you to start thinking about things like doing multiple sessions per day or targeting multiple brain areas," Downar said.

This is part 1 of a 3-part interview series with Jonathan Downar, MD, on TMS practice and his group's new meta-analysis on dosing in accelerated rTMS.

Holtzheimer PE 3rd, McDonald WM, Mufti M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. 

Goldstein-Piekarski AN, Ball TM, Samara Z, et al. Mapping Neural Circuit Biotypes to Symptoms and Behavioral Dimensions of Depression and Anxiety. 

Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. 

Derman C. TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home. HCPLive. Published May 15, 2026. Accessed August 25, 2026. 

https://www.hcplive.com/view/tms-mdd-faster-fewer-visits-home

Videos

Downar says shorter sessions, accelerated schedules, and expanding neuroimaging maps have made TMS effective for more patients in far fewer visits.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Ali Mehdi, MD, MEd, is a board-certified nephrologist at Cleveland Clinic, where he also serves as assistant professor of medicine at the Lerner College of Medicine at Case Western Reserve University.

IgA nephropathy (IgAN) is no longer considered the benign disease it was once thought to be, with a growing share of patients now expected to eventually need renal replacement therapy.

HCPLive: IgA nephropathy care has changed dramatically in a relatively short period of time over the last few decades. What do you think has been the biggest paradigm shift in how clinicians should think about this disease?

Mehdi: I think the biggest thing that we've learned over the past few years is that IgA nephropathy is not the benign disease that we all unfortunately learned back in medical school and as nephrology fellows. We now realize that a big percentage of patients, even those who present with a seemingly indolent disease, will end up requiring renal replacement therapy at some point down the line. In a disease like IgA, the problem is that this could be decades down the line, but when you think of a disease that really starts at age 30 or 40, decades down the line is still a young adult, basically. So I think that's been the biggest realization about IgA, and that clearly made its way into the updated KDIGO guidelines for how we should be managing IgA nephropathy. It has already transformed how we approach, how we diagnose, how we risk stratify, and how we treat those patients.

HCPLive: IgAN is a heterogeneous disease, with patients experiencing different rates of progression and treatment responses. How should clinicians account for that variability when making treatment decisions?

Mehdi: We are still learning how to risk stratify our patients. IgA nephropathy is a heterogeneous disease. We have patients who present with fast, progressive kidney disease where they lose kidney function pretty rapidly over a few years, and we have patients who have hematuria and proteinuria with an indolent progression toward the need for renal replacement therapy down the line. We do have some ways to monitor these patients and risk stratify based on clinical parameters like proteinuria and estimated GFR, and then pathologic parameters that we get from a kidney biopsy, and that helps us establish the risk of progression toward end-stage kidney disease in the foreseeable future. That is not a perfect way to do it, and we are learning more from clinical trials about how to better identify which patient would benefit from what. That is an evolving chapter that's being written, and the heterogeneity doesn't help, but there's a lot of data hopefully coming over the next few years.

HCPLive: What is one change you hope to see in IgA nephropathy care over the next few years?

Mehdi: I think the biggest change I would like to see is being better able to phenotype patients to realize who would benefit from what treatment when. I think that would help us drastically, as opposed to relying on biomarkers of disease, biomarkers of the damage that's already been set, meaning estimated GFR slope and proteinuria. I'd like to be able to better phenotype my patients based on disease parameters that would tell me that this patient is high risk and would benefit from treatment X or Y, or would not benefit from treatment X or Y. I think that is bound to happen over the next 5 to 10 years, and it will dramatically shift the way we treat and manage our patients.

Kidney Disease: Improving Global Outcomes (KDIGO) IgAN/IgAV Work Group. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). 

Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. 

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Strategic Alliance Partnership

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

 has granted marketing authorization to the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, the first wearable device in the US to continuously track ketone levels and the first worldwide to pair continuous ketone and glucose monitoring in a single sensor.

What is the Libre Duo 10 Day authorized for?

The FDA authorized the device to continuously monitor glucose and ketone levels in patients aged two years and older living with diabetes.

A wearable sensor measures glucose and ketone concentrations in interstitial fluid every minute over a 10-day wear period and transmits readings wirelessly to a compatible smartphone.

What data supported the FDA authorization?

Abbott Diabetes Care submitted accuracy data from six clinical studies enrolling more than 600 participants, reviewed by the FDA through the De Novo premarket pathway.

The authorization, announced by parent company Abbott on August 25, 2026, covers patients aged ≥2 years living with 

. The device measures both analytes in interstitial fluid every minute across a 10-day wear period and sends readings wirelessly to a compatible smartphone.

"Today's authorization is a breakthrough for the safety of children and adults living with diabetes,” Michelle Tarver, MD, PhD, director of the FDA’s Center for Devices and Radiological Health, said in a statement. “Knowing that ketone levels are rising, and having that information in real time, around the clock, can be the difference between early intervention and a life-threatening emergency.”

Prior to this authorization, patients needing to track ketones relied on point-in-time urine or blood tests incapable of showing directional trends. Continuous glucose monitoring has become standard for many patients with 

, but ketone surveillance remained a separate, intermittent process disconnected from real-time glucose data. The Libre Duo 10 Day closes this gap by unifying both measurements on one platform capable of flagging rising ketones before diabetic ketoacidosis develops.

The FDA's authorization rests on clinical and performance data submitted by Abbott Diabetes Care across 6 clinical studies enrolling >600 participants aged ≥2 years. Investigators evaluated the accuracy of the device's glucose and ketone sensing functionality across a wide range of glucose and ketone concentrations. Results demonstrated the sensor consistently tracked clinically meaningful shifts in ketone levels throughout the full 10-day wear period, including detection of rising ketone concentrations preceding onset of diabetic ketoacidosis.

The FDA reviewed this evidence through the De Novo premarket pathway, reserved for low- to moderate-risk device types without an existing predicate. Abbott's submission followed a Breakthrough Device designation, granted earlier in development to expedite review of technologies addressing life-threatening or irreversibly debilitating conditions. Specific sensor accuracy statistics, such as mean absolute relative difference, do not appear in the FDA release, leaving device-level performance figures for clinicians to seek once product labeling becomes available.

Libre Duo 10 Day regulatory pathway and safety controls

The device issues automatic alerts when ketone concentrations cross a threshold associated with elevated risk, intended to prompt patients and caregivers to act before diabetic ketoacidosis becomes a medical emergency. FDA notes ketone readings should be interpreted alongside glucose trends and clinical symptoms rather than as a standalone value. Alongside the De Novo authorization, the agency established special controls governing labeling and performance testing requirements applicable to the Libre Duo 10 Day.

These special controls extend to any subsequent device of this type seeking market entry through the same classification. Combined with general controls already applicable to class II devices, they are intended to provide reasonable assurance of safety and effectiveness for this newly created device category.

U.S. Food and Drug Administration. FDA authorizes first wearable device that continuously monitors both ketone levels and blood sugar. Published August 25, 2026. Accessed August 25, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar

Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed August 25, 2026. 

https://www.cdc.gov/diabetes/php/data-research/index.html

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

Type 1 Diabetes

Type 2 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes

Wojciech Zareba, MD, PhD, is a professor of medicine and cardiology at the University of Rochester Medical Center.

The KardiaMobile 6-Lead (KM6L) portable electrocardiographic (ECG) recorder has demonstrated its superior ability to detect 

 when self-administered by patients compared to traditional ambulatory monitoring.

Kardia’s 6-Lead ECG Detects More Arrhythmia Events than Guideline-Recommended Devices

Traditionally, ambulatory ECG monitoring has depended on guideline-recommended 24- or 48-hour Holter monitors, which possess limited sensitivity given the inherent infrequency of arrhythmic events. Symptoms such as palpitations, dizziness, and lightheadedness, while prevalent, are often transient, leaving many ECG monitors unable to detect them reliably. To this end, AliveCor’s KM6L allows patients to initiate recordings manually via handheld devices, capturing arrhythmias as they happen. The present study compares the efficacy of the KM6L with that of existing extended ECG monitoring like Holter recordings.

“When we started the study, it took some time to make sure that people were well versed in these recordings, but we learned how to train them better,” Wojciech Zareba, MD, PhD, professor of medicine and cardiology at the University of Rochester Medical Center and a lead investigator in the study, told 

 in an exclusive interview. “And ultimately, the majority of patients provided us with good quality recordings, which were crucial to determine whether there was any cardiac arrhythmia or not.”

Zareba and colleagues conducted a prospective, single-center cohort study including patients recruited from outpatient cardiology clinics at the University of Rochester. Patients were eligible for inclusion if they were ≥18 years of age and had been referred for ambulatory ECG monitoring due to unexplained lightheadedness, dizziness, or palpitations. Patients with a history of unexplained syncope in the past year were excluded.

At the initial visit after each enrollment, patients were supplied with a KM6L device or a Holter monitor and were instructed in its operation and use via the Kardia smartphone app. Patients performed a supervised ECG recording, obtaining a 6-lead, 1-minute recording to ensure correct operation. Additionally, patients were required to complete 4 daily scheduled asymptomatic recordings to establish a baseline.

Follow-up assessments were conducted at 5 +/-2 days, 17 +/- 2 days, and 32 +/- 2 days post-enrollment. The study’s primary endpoint was the detection of clinically significant arrhythmias, defined a priori as atrial fibrillation or flutter lasting ≥30 seconds, supraventricular tachycardia, second- or third-degree atrioventricular block, pauses ≥3 seconds, or wide complex tachycardia.

A total of 350 patients were enrolled in the study, with 40% (n = 140) receiving a 24- or 48-hour Holter and 60% (n = 210) using an extended patch ECG monitor, including 49.7% (n = 105) with a 2-day patch, 14.7% (n = 31) with a 7-day patch, and 35.6% (n = 74) with a 14-day patch. 22.3% of patients had prior arrhythmia, while 24.6% reported having palpitations in the past requiring cardiac monitoring.

Investigators collected a total of 6251 KM6L recordings, with a median of 15 recordings per patient (interquartile range [IQR], 7-150 recordings per patient). Significant arrhythmias were detected in 66 patients (18.9%) using either ambulatory ECG monitoring or KM6L – the former identified arrhythmias in 27 patients (7.7%), while KM6L identified arrhythmias in 52 patients (14.9%). Additionally, 39 arrhythmia episodes (11.1%) were detected exclusively by KM6L (

 = .0008), most commonly atrial fibrillation (n = 23).

Ultimately, Zareba and colleagues concluded that the KM6L device is capable of detecting arrhythmias otherwise frequently missed by Holter monitoring, while being easy to use and engendering high patient satisfaction. Overall, the team notes that the device may improve arrhythmia detection and patient management, as well as reduce healthcare costs, if applied to routine clinical practice.

“Another very important element of this particular device is that you may be able to provide some additional information for patients who might be healthy,” Zareba said. “They might be a bit nervous, they might be anxious, and they don’t have any serious arrhythmia – finding this out here is much better for them than going through the next steps of diagnostic procedures, echoes or invasive procedures.”

Editors’ Note: Zareba reports no relevant disclosures.

Dzikowicz DJ, Aktas MK, Horn R, et al. Symptom-triggered 6-lead ECG monitoring significantly increases arrhythmia detection beyond traditional ambulatory monitoring. 

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/hrs guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1). 

Wojciech Zareba, MD, PhD, discusses his recent study comparing the efficacy of the KardiaMobile 6-Lead to Holter ambulatory ECGs.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

A nephrologist details gaps in tracking CKD screening, labs, and treatment in correctional care.

Chronic Kidney Disease

CKD Care Gaps for Incarcerated Patients, With Laura Maursetter, MD

Jennifer A. Dantzer, MD, MHS, assistant professor of pediatrics, Johns Hopkins University School of Medicine.

IMPACT-PLuS follow-up data show 35% of children treated with peanut OIT had a reaction years later, with 5 requiring epinephrine, Jennifer Dantzer, MD, says.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

IMPACT-PLuS Data Show Low but Real Reaction Risk with Peanut OIT

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Icodec-Semaglutide Combo Outperforms Glargine in T2D

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Nipocalimab-aahu (IMAAVY) is now approved for wAIHA, based on Phase 2/3 ENERGY trial data showing durable hemoglobin response.

FDA News

Hematology

Anemia

FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

Anatomy separated the sinuses from the lungs, and specialty training reinforced the split. The panel makes the case that the evidence describes a single organ with one disease process.

Video Series

The Unified Airway: Linking Severe Asthma and Sinus Disease

This episode, "Complement Inhibition in IgAN: Interpreting the APPLAUSE Trial," features the panel weighing a landmark trial.

Complement Inhibition in IgAN: Interpreting the APPLAUSE Trial

Charles Lynde, MD, is an associate professor in the Department of Medicine at the University of Toronto. He is the also Chief Medical Director of Lynde Institute for Dermatology and Lynderm Research.

In this segment of his Q&A interview, Charles Lynde, MD, reviews upadacitinib's safety profile in the UP-AA trials and how it could reshape alopecia areata care.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q&A: Upadacitinib's Safety Profile and Role in Severe Alopecia Areata Care

The assumption that anti-alarmin therapy is the answer for low T2 disease meets the trial evidence. Dr. Wechsler walks through where the efficacy signal actually concentrates.

Low T2 Asthma: What Anti-TSLP Data Show in Low-Eosinophil Patients

In "IgAN Pathogenesis and the Rationale for Complement Inhibition," our experts connect disease mechanism to drug targets.

IgAN Pathogenesis and the Rationale for Complement Inhibition

In this Q&A, Charles Lynde, MD, highlighted upadacitinib's impact on severe alopecia areata in new phase 3 data addressing the hair loss condition.

Latest News

Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments

TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes

Kardia’s 6-Lead ECG Detects More Arrhythmia Events than Guideline-Recommended Devices